Home » Posts tagged with » SARS-CoV-2
Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from the European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According to the US pharma company, the conditional marketing authorization for Veklury was given in the interest of public health because of the coronavirus pandemic […]

Imperial College begins human trial of coronavirus vaccine candidate COVAC1

Imperial College London said that it has dosed the first healthy volunteer with its COVAC1 coronavirus vaccine candidate, which has been developed using the new self-amplifying RNA (saRNA) technology. The university claimed that the COVID-19 vaccine candidate has gone through rigorous pre-clinical safety tests, and in animal studies, it has been demonstrated to be safe, […]

Continue reading …
Merck completes acquisition of Austrian vaccine developer Themis Bioscience

Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer Themis Bioscience. The Austrian company is focused on developing vaccines and immune-modulation therapies for infectious diseases and cancer. Merck announced the deal last month in a move to gain access to Themis Bioscience’s coronavirus vaccine candidate. Read more about Merck acquisition […]

Continue reading …
Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib

Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib is an oral JAK1/JAK2 inhibitor, which was licensed by Lilly from Incyte. Marketed as OLUMIANT, baricitinib has approval in […]

Continue reading …
Sinovac Biotech CoronaVac COVID-19 vaccine candidate succeeds in phase 1/2 trial

Sinovac Biotech said that the phase 1/2 clinical trial for its coronavirus vaccine candidate CoronaVac has delivered positive preliminary results by showing favorable immunogenicity and safety profiles. According to the Chinese biopharma company, the phase 1/2 clinical trials are randomized, double-blind and placebo-controlled studies featuring 743 healthy volunteers, aged between 18 and 59 years. Of […]

Continue reading …
Intranasal COVID-19 vaccine : Intravacc, WBVR and Utrecht University join forces for vaccine development

Dutch vaccine maker Intravacc has forged a partnership with Wageningen Bioveterinary Research (WBVR) and Utrecht University in the Netherlands to develop an intranasal COVID-19 vaccine. The public-private partnership will combine Intravacc’s vaccine development technology with WBVR’s viral vector technology and animal technologies and the Dutch university’s expertise in coronavirus. According to Intravacc, the potential coronavirus […]

Continue reading …